Foghorn Therapeutics Inc. (NASDAQ:FHTX)’s stock price traded down 6.7% on Friday . The stock traded as low as $14.01 and last traded at $14.01. 101 shares changed hands during trading, a decline of 100% from the average session volume of 101,467 shares. The stock had previously closed at $15.02.
Separately, Zacks Investment Research cut Foghorn Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, September 13th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $22.00.
The company has a market capitalization of $524.51 million and a P/E ratio of -2.28. The company has a debt-to-equity ratio of 0.19, a current ratio of 8.81 and a quick ratio of 8.81. The company has a fifty day moving average price of $11.13 and a two-hundred day moving average price of $11.19.
Foghorn Therapeutics Company Profile (NASDAQ:FHTX)
Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Receive News & Ratings for Foghorn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foghorn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.